<DOC>
	<DOCNO>NCT01218139</DOCNO>
	<brief_summary>Neurofibromatosis type 1 ( NF1 ) frequent , autosomal dominant disorder cause heterozygous mutation ( intragenic microdeletion ) NF1 tumor suppressor gene ( chr.17q11.2 ) . One clinical feature development benign malignant tumor . The common benign tumor patient tumor peripheral nerve sheath , name neurofibroma ( cutaneous , subcutaneous plexiform ) . Every NF1 patient life time risk 8 13 % develop malignant peripheral nerve sheath tumor ( MPNST ) pre-existing neurofibroma . In patient NF1 microdeletion ( 5 % NF1 patient ) , risk even twice high compare patient intragenic mutation . MPNSTs lead bad prognosis patient , overall five-year survival le 25 % . To know development progression tumor , screen microarray comparative genome hybridization ( Leuven ) full exome sequencing ( Leuven ) . Further experiment do cooperation ( bidirectional ) foreign labs Victor Mautner ( Germany ) , André Bernards ( USA ) , Karen Cichowski ( USA ) Yuan Zhu ( USA ) . For experiment , make use tumoral rest material remove NF1 patient .</brief_summary>
	<brief_title>Analysis Peripheral Nerve Sheath Tumors ( PNSTs ) Neurofibromatosis Type 1 ( NF1 ) Patients</brief_title>
	<detailed_description>Introduction Neurofibromatosis type 1 ( NF1 ) autosomal dominant disorder occur 1 3500 living newborn . The disease cause heterozygous mutation NF1 gene , locate chromosome 17q11.2 . The NF1 gene encodes tumor suppressor neurofibromin , negative regulator RAS/MAPK pathway . In approximately 95 % patient , heterozygous mutation intragenic . The remain 5 % patient carrier microdeletion , mostly type 1 deletion , apart NF1 gene , 14 additional protein cod gene locate . Clinically , NF1 patient café-au-lait macula , freckling , Lisch nodules neurofibromas . Also cognitive problem , bone lesion optic pathway gliomas common patient . Neurofibromas benign neoplasms peripheral nerve sheath , appear everywhere body almost every NF1 patient . Neurofibromas compose different cell type like Schwann cell , fibroblast , mast cell perineurial cell . If Schwann cell NF1 patient wild-type NF1 allele inactivate heterozygous microenvironment , neurofibroma form . There 3 type neurofibromas : cutaneous , subcutaneous plexiform . Cutaneous subcutaneous neurofibromas appear adolescence isolated nodule skin , respectively . Plexiform neurofibromas congenital spread along large segment peripheral nerve . NF1 microdeletion patient general neurofibromas appear young age . Every NF1 patient life time risk 8 13 % develop malignant peripheral nerve sheath tumor ( MPNST ) pre-existing ( plexiform ) neurofibroma . This risk even twice high NF1 microdeletion patient compare patient intragenic mutation . MPNSTs difficult diagnose early phase large number tumor diverse location . These tumor infiltrate easily surround tissue frequently give rise metastasis . At moment , available treatment surgical removal MPNSTs . Complete resection often difficult due size tumor location important nerve . The five-year survival patient MPNSTs less 25 % . Research protocol All NF1 patient link UZ Leuven . Their follow-up do Prof. Dr. Eric Legius . When patient suspect MPNST , patient refer surgeon clinical oncology department , respectively . Also neurofibromas remove cause problem patient . As part different tumor care program hospital , tumor piece send pathology centre human genetics routine genetical analysis , like karyotyping . In lab neurofibromatosis research , rest material frozen tumor piece dissociate cell research purpose . The sample store database system accessible neurofibromatosis research group . In cooperation group Victor Mautner Karen Cichowski , tumor database complete NF1 tumor material cell line . The latter sample cod could use part collaboration . Experimental approach In literature , little know development MPNST neurofibroma . In study want gain insight process , end lead well diagnosis treatment NF1 patient MPNSTs . For purpose , frozen rest material neurofibroma MPNSTs use . At first , DNA extract frozen tumor piece ( neurofibromas MPNSTs ) . Together blood DNA ( also rest material ) , tumor DNA screen microarray genomic hybridization . This technique allow u check chromosomal abnormality , like amplification deletion , much high resolution traditional cytogenetics . In way , look recurrent alteration within certain tumor type similarity difference benign malignant tumor . Secondly , group MPNSTs subdivide tumor derive NF1 microdeletion patient tumor patient intragenic mutation . Recurrent chromosomal gain loss compare 2 group . This show u mechanism tumor development progression different NF1 microdeletion patient . In cooperation group André Bernards Karen Cichowski , try elucidate role NF1 microdeletion development neurofibroma . Our group collect tumor sample grow Schwann cell fibroblasts tumor . The frozen vial tumor piece culture cell encode provide labs part collaboration . Subsequently , DNA derive 10 different tumor ( neurofibromas MPNSTs ) match blood DNA analyze 'full exome sequencing ' check mutation cod exon . In collaboration group Yuan Zhu , tumor sample send retrieve encoded way . This study perform Eline Beert , PhD student lab neurofibromatosis research , part achieve degree 'Doctor Biomedical Sciences ' , Prof. Dr. Eric Legius promotor main researcher . Only Catholic University Leuven foreign university , commercial partner ( like company ) participate study . The result obtain described experiment consider pure scientific information none report patient .</detailed_description>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurofibromatosis 1</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<criteria>NF1 patient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>neurofibroma</keyword>
	<keyword>MPNST</keyword>
	<keyword>array CGH</keyword>
	<keyword>sequence</keyword>
</DOC>